Gamma Knife®
Gamma Knife® Stereotactic Radiosurgery offers a relatively non-invasive procedure in which a single highly concentrated dose of ionizing radiation is delivered to a precisely localized intracranial target. Using three-dimensional computerized dosimetry, the Gamma Knife® focuses narrow beams of cobalt-60 radiation through 201 portals distributed around the patient’s head, creating an exact intersection of beams meticulously conforming to the location, size and shape of the target. Candidates for Gamma Knife® treatment include selected patients with surgically difficult problems, such as:

  • Arteriovenous malformations
  • Benign intracranial tumors, including acoustic neuromas, meningiomas, pituitary adenomas, craniopharyngiomas, pineal tumors and hemangioblastomas
  • Metastatic intracranial lesions
  • Other malignant tumors, such as glial tumors, chordomas, glomus tumors and nasopharyngeal carcinoma
  • Patients with residual lesions left after previous open neurosurgical procedures
  • Patients undergoing conventional radiation therapy, needing boost dose
  • Patients with recurrent tumors
  • Patients at high risk for surgical complications, due to age or underlying medical problems
  • Selected patients with trigeminal neuralgia

The CyberKnife Robotic Radiosurgery System is the world’s first and only radiosurgery system designed to treat tumors anywhere in the body with sub-millimeter accuracy. Using image guidance technology and computer controlled robotics, the CyberKnife System is designed to continuously track, detect and correct for tumor and patient movement throughout the treatment. Because of its extreme precision, the CyberKnife System does not require invasive head or body frames to stabilize patient movement, vastly increasing the system’s flexibility. Unlike traditional radiosurgery systems that can only treat tumors in the head and neck, the CyberKnife System can treat both intracranial and spinal tumors. The CyberKnife System provides an additional option to many patients diagnosed with previously inoperable or surgically complex tumors.